designed a CD47/PD-L1 bispecific antibody, namely IBI322, that selectively binds to CD47+ PD-L1+ tumor cells to trigger intense phagocytosis of tumors by macrophages and enhance T-cell activation. Here, CD47 is linked to neoplasm.